The spatial organization of non-homologous end joining: From bridging to end joining

Takashi Ochi*, Qian Wu, Tom L. Blundell

Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, UK

ARTICLE INFO

Article history:
Received 17 September 2013
Received in revised form 27 January 2014
Accepted 10 February 2014
Available online 11 March 2014

Keywords:
Non-homologous end joining DNA-PKcs Artemis, DNA ligase IV XRCC4 XLF Cernunnus LIG4 syndrome

ABSTRACT

Non-homologous end joining (NHEJ) repairs DNA double-strand breaks generated by DNA damage and also those occurring in V(D)J recombination in immunoglobulin and T cell receptor production in the immune system. In NHEJ DNA-PKcs assemblies with Ku heterodimer on the DNA ends at double-strand breaks, in order to bring the broken ends together and to assemble other proteins, including DNA ligase IV (LigIV), required for DNA repair. Here we focus on structural aspects of the interactions of LigIV with XRCC4, XLF, Artemis and DNA involved in the bridging and end-joining steps of NHEJ. We begin with a discussion of the role of XLF, which interacts with Ku and forms a hetero-filament with XRCC4; this likely forms a scaffold bridging the DNA ends. We then review the well-defined interaction of XRCC4 with LigIV, and discuss the possibility of this complex interrupting the filament formation, so positioning the ligase at the correct positions close to the broken ends. We also describe the interactions of LigIV with Artemis, the nuclease that prepares the ends for ligation and also interacts with DNA-PK. Lastly we review the likely affects of Mendelian mutations on these multiprotein assemblies and their impacts on the form of inherited disease.

© 2014 The Authors. Published by Elsevier B.V. Open access under CC BY license.

1. Introduction

Non-homologous end joining (NHEJ) is an evolutionarily conserved repair system for DNA double-strand breaks (DSBs) [1]. NHEJ not only repairs DNA ends generated by DNA damage but also joins those created by V(D)J recombination and class switch recombination, which are joined in a strictly regulated way in order to maintain the gene integrity for immunoglobulin and T cell receptors in the immune system. NHEJ involves two pathways: classical NHEJ (referred to as NHEJ in this review) and alternative end joining (AEJ). NHEJ and AEJ use different proteins and AEJ requires micro-homology of DNA ends [2–6]. In this review, we focus on structural aspects of NHEJ.

The core components of NHEJ are the Ku70/80 heterodimer (Ku), DNA-dependent protein kinase catalytic subunit (DNA-PKcs), XRCC4, DNA ligase IV (LigIV) and XLF/Cernunnus (XLF). Ku and DNA-PKcs together with DNA form the DNA-PK complex, and XRCC4, LigIV and XLF form the NHEJ ligase complex. In addition, NHEJ requires Artemis, DNA polymerase μ and λ (pol μ and pol λ, respectively), terminal dinucleotidyltransferase (TdT), polynucleotide kinase-phosphatase (PNKP), aprataxin (APTX) and aprataxin-PNKP-like factor (APLF) [1]. 53BP1 and RIF1 play important roles in responding to DSBs in the early stages of NHEJ [7–12]. Thus, the DNA-PK and NHEJ ligase complexes share many common partners, for example, XLF, Ku and DNA itself, and contribute at DNA ends to much larger multicomponent assemblies, which vary over space and time depending on the type of DSB (Fig. 1).

2. DNA-PK complex

Most work on understanding the DNA-PK sub-complex has been focused on DNA-PKcs, the catalytic subunit, which belongs to the phosphoinositide 3-kinase (PI3K)-related protein kinase (PIKK) family. Several groups have analyzed the structure of DNA-PKcs using single particle reconstruction from cryo-electron microscopy [13–18]. Although these models differ quite radically between themselves, general features such as head/crown containing the kinase structure and a large circular base can be seen in all.

Sibanda et al. (2010) produced crystals and have reported the structure of DNA-PKcs in complex with the C-terminal domain of Ku80 at 6.6Å resolution [19]. In the electron density helical regions were clearly visible indicating that most of the structure was dominated by HEAT or other related α-helical repeats. However, the electron density for the chains linking these helices was...
missing in most cases, making the polypeptide path difficult to follow; the exception was the kinase domain where prior knowledge of the fold assisted the interpretation. Nevertheless, in the N-terminal region helices are clearly identified in HEAT repeats and folded into a circular structure, resembling a cradle when viewed from the side (see Fig. 2). The C-terminal region, which forms the head/crown of the molecule, is also predominantly α-helical. It contains the protein kinase domain, which is involved in phosphorylation of other proteins as well as autophosphorylation and is well positioned for access to substrates (Fig. 2). Recently Pavletich and colleagues have solved the structure of the mammalian target of rapamycin (mTOR), a further phosphoinositide 3-kinase-related protein kinase, which controls cell growth in response to nutrients and growth factors [20]. The arrangement of helices corresponds to that conservatively reported in the structure of DNA-PKcs. Ongoing X-ray structural work (BL Sibanda, D Chirgadze and TL Blundell, unpublished) at 4.3 Å resolution has defined the positions of all the equivalent helices and suggests a number of putative interaction regions shared with mTOR.

The poor resolution of the analysis and the fact that the Ku80 C-terminal domain also consists of α-helical HEAT repeats makes it difficult to locate this domain in the electron density with any certainty but it likely resides within the large N-terminal circular structure. This domain is a good candidate for DNA binding, and a putative DNA-binding sub-domain was proposed in the cryo-EM structure reported earlier [17]. Indeed the evolution of a large head domain conserved in other PI3K-related protein kinases together with a large ring structure allows DNA-PKcs to function both as an enzyme involved in DNA damage signaling and as a platform for DNA, Ku and other proteins engaged in the repair of broken DNA.

3. End bridging

XLF, a key protein in NHEJ, was discovered independently through yeast two-hybrid screening for XRCC4 interactors and investigations of a group of patients with growth retardation, microcephaly and immunodeficiency characterized by a profound T+B lymphocytopenia [21–23]. Down-regulation of XLF in cells causes an increase of radiosensitivity, sensitivity towards anti-cancer drugs, DSB repair defects and prolonged phosphorylation of histone H2AX [22]. Cells from patients carrying mutations in the XLF gene have impaired ability to respond to replication stress [24]. XLF is less abundant in cells compared to XRCC4 and LigIV [22]. XLF, like XRCC4, does not have enzymatic function itself, but rather performs its role in NHEJ as a scaffold protein to stabilize LigIV/XRCC4 at broken DNA ends. It enhances the LigIV/XRCC4 end-joining process specifically through LigIV readynylation following ligation [25–28]. How exactly XLF improves LigIV function and whether XLF is involved in early synopsis of NHEJ are central questions for investigation.

Structural studies of XLF and the XRCC4/XLF complex provide powerful starting points for an investigation of the functional mechanism of XLF. Despite the low sequence identity, the crystal structures of XLF and XRCC4 demonstrate that the two proteins are homologous homodimers comprising globular head domains and C-terminal helices that form coiled-coil tail structures [29–32]. The head domains form seven-stranded antiparallel β-sheets sandwiching a helix-turn-helix (HTH) motif between β4 and β5, but XLF contains an extra helix in the N-terminal region. Whereas the tail structure of XRCC4 comprises an elongated coiled-coil, the equivalent extended helix α6 of XLF is followed by further helices, α5 and

Fig. 1. Schematic representation of the NHEJ network. Grey lines indicate protein–protein interactions [64,80,88–90,161–170].

Fig. 2. Molecular surface of the DNA-PKcs structure viewed perpendicular to the ring structure (left panel) and in the plane of the ring structure (right panel). The color code of the molecule is as follows: the ring structure is green; the forehead that is part of the ring structure is light purple; the putative DNA binding domain is pink; the larger C-terminal part is magenta, and the kinase domain is yellow (Adapted from ESRF Highlights, Newsletter, and Management Reports 2010 by BL Sibanda, D Chirgadze & TL Blundell).
α6; these fold back around the coiled-coil formed by α4 so that the C-termini come close to the α1 helices of the head domains.

Mutagenesis studies have demonstrated the interactions between XRCC4 and XLF are through head domains of each protein, and key interactions are conserved, exposed and located in HTH motif and β6–β7 structure for both proteins [32,33]. These key residues are symmetrically related by the dyads of the XRCC4 and XLF homodimer head domains, suggesting that XRCC4/XLF might form higher order polymers. Crystal structures, SAXS (small angle X-ray scattering) and nanospray mass spectrometry of XRCC4/XLF (both of which are C-terminal truncated) confirm this prediction [34–38]. Four structures solved in different laboratories show similar alternating XRCC4/XLF helical polymers with left-handed six-fold screw axes (Fig. 3A) [34–36,38]. The binding of the two proteins generates a tilt angle between the pseudo dyads relating the head domains and coiled-coil tail structures. The four XRCC4/XLF structures differ in the angles of rotation between the helical-tail structures of XRCC4 and XLF dimers, and this in turn leads to differences of curvature and sizes of the central cylindrical cavities when XRCC4/XLF forms higher order polymers [34–36,38] (Fig. 3A). The effects of a small twist between two head domains, with the interaction anchor regions still in touch, are amplified through the long tail structures, demonstrating that XRCC4/XLF filaments are flexible and elastic (Fig. 3C).

XRCC4/XLF filament

Fig. 3. The structure of the XRCC4/XLF complex. (A) XRCC4/XLF structures solved in four different groups [34–36,38]. One turn of XRCC4/XLF filament, which contains 6 copies of each XRCC4 and XLF molecules, is generated for comparison. Superimposition of the first XLF dimer molecules demonstrates varying curvatures of the filaments. (B) Superimposition of the head domains from XLF, XRCC4 and SAS-6, β6-7 and HTH are closer together in XLF than in XRCC4 and SAS-6. The PDB codes for structures here are 1HK9 (XRCC4), 2QM4 (XLF) and 2Y3V (SAS-6) [39,40,51]. (C) The protein–protein interface of XRCC4/XLF, located in the head domain of each protein. The hydrophobic interface is shown in the top panel, while the bottom panel shows the polar interaction (indicated by grey dashed line). XLF is colored in red pink and XRCC4 is in deep purple. The XRCC4/XLF structure used is from [45].

XRCC4/XLF interface is formed mainly through hydrophobic interaction. The tips of these loops (α2–3 and β6–7) are in close proximity and form a hydrophobic patch in XLF. Key residue L115 in β6–β7 inserts into the hydrophobic pocket of XRCC4 (formed by α1-2 and β6–7) created by residues M61, L101 and F106 (Fig. 3C Top). XLF L65 (in α2-3 loop) aligns next to the XRCC4 hydrophobic pocket. In addition, XRCC4/XLF is further stabilized by polar interactions. Residues from XLF α2–3 loop R64 and T66 interact with XRCC4 E55 (in α1) and S105 (in β7), respectively (Fig. 3C Bottom). Although the interactions between XRCC4 and XLF protofilaments in the fibres are mediated through head domains, the C-terminal structures of XRCC4 and XLF impact positively on the strength of the interaction [36,38].

The identification of a rather small and flexible interaction region between XRCC4 and XLF should allow small molecules or peptides to be designed to disrupt the XRCC4/XLF interaction. Over-expression of XRCC4 mutants, which cannot bind to XLF, increase the radiosensitivity of wild-type CHO cells [39]. Thus, small molecules that inhibit XLF and XRCC4 interaction might prove beneficial to cancer patients for radiochemotherapy treatment. Interestingly, crystal structures of the N-terminal regions of the centriole protein SAS-6 have revealed a protein fold similar to those of XLF and XRCC4 [40–42]. Alignment of the head domains of XLF, XRCC4 and SAS-6 shows the same general folding, but a greater structural similarity between XRCC4 and SAS-6 in relative positioning of β6–7 loop and HTH structure (Fig. 3B). Indeed a higher order SAS-6 complex is formed through equivalent head–to–head interactions as seen in the XRCC4/XLF complex and coiled-coil tails of the SAS-6 dimers extend outwards towards the assemblies of microtubules.

DNA interactions with individual XRCC4 and XLF molecules are not strong and large pieces of DNA are required for stable protein–DNA interactions [27,43]. Andres and co-workers [45] have shown that XLF K293 and XRCC4 E170 and R192 are key residues for individual protein interaction with DNA. The XLF C-terminal is crucial for the interaction of the XRCC4/XLF with DNA. Thus, only full length XRCC4/XLF can mediate the DNA-bridging effect. Addition of LigIV BRCT domain or use of truncated XLF and XRCC4 proteins disables the DNA-bridging property. On the basis of these observations, two types of interaction are implicated in mediating DNA bridging: filament–DNA and filament–filament. Disruption of either leads to failure of the DNA-bridging process. The LigIV BRCT domain–binding site on XRCC4 overlaps with the probable region of XRCC4 tetramerization. Therefore this filament–filament interaction could come from the tetramerization of XRCC4 [35]. XRCC4/XLF-filament assemblies seen in both crystal structures and EM studies [34–36,38], and strong DNA binding and bridging could therefore achieved through XRCC4/XLF filament bundles containing more than one copy of the XRCC4/XLF filament. Ku and DNA-PKcs can mediate DNA synopsis [44]. XRCC4/XLF DNA bridging does not require the presence of Ku and DNA-PKcs [35]. Since Ku binds to DNA damage sites before XRCC4 and XLF, it is not known whether Ku can further improve XRCC4/XLF DNA bridging or whether they share some degree of redundant function. The C-terminal structures of XRCC4 and XLF are both targeted for phosphorylation by DNA-PKcs [45,46]. Phosphorylation of XLF residues in the unstructured C-terminal region has no effect on XLF recruitment to damaged chromatin, DNA binding and repair efficiency [47,48]. But the phosphorylation of XRCC4/XLF by DNA-PKcs can disassemble the XRCC4/XLF filament formation [39]. Therefore DNA-PKcs may be one of factors involved in XRCC4/XLF filament regulation.

The crystal structure of XRCC4 in complex with the BRCT domains of LigIV shows that the second BRCT domain of LigIV (BRCT2; residues 815–911) interacts with the coiled-coil region of XRCC4 and is positioned close to the head domain of one XRCC4.
protomer [49,50]. The presence of BRCT domains bound to XRCC4 does not interfere with the formation of an individual XRCC4/XLF filament. However, in the presence of full length LiggIV, filament formation is disrupted, presumably due to the presence of the LiggIV catalytic domain [51], which may limit access of XLF to one side of the XRCC4 homodimer head domain and therefore reduce filament formation. This termination of the XRCC4/XLF filament formation by LiggIV could be a regulatory process important for the role of the filament in the DNA double-strand break damage repair, as the XRCC4/XLF polymer would be terminated, thereby placing the ligase near a DNA end.

Alignment-based gap filling by DNA polymerase polα and polμ in whole-cell extracts is completely dependent on XLF [52]. In XRCC4 deficient cell lines, disruption of the interaction between XLF and XRCC4 using XRCC4 mutants can restore the signal end joining, but not the coding end-joining function [39]. Therefore it is tempting to explain these functions of XLF in terms of its ability to form filaments with XRCC4, which stabilize and align the DNA ends, increasing DNA ligation efficiency.

The flexibility of the XRCC4/XLF filament opens up the possibility that it might wrap around chromatin and interact with DNA and histones. The DNA binding region of XLF would be located on the inner side of the XRCC4/XLF helical structure. DNA would wrap around the outer histones of the nucleosome as a left-handed helical structure; the XRCC4/XLF is also a left-handed helical filament structure, although the helix pitch is much greater than that of DNA super-helical packing in the nucleosome. However, it could stabilize DNA strands after nucleosome disassembly and damaged DNA is exposed for ligation. Live cell imaging techniques have identified the immediate recruitment of XLF to laser-induced DSBS with only Ku protein bound in vivo, and the presence of XRCC4 can stabilize XLF-DNA interaction through slowing of the highly dynamic exchange rate between bound and free XLF and DNA [53]. Protein interaction assays have confirmed the interaction between the core structure of Ku and the extreme C-terminal of XLF only in the presence of DNA while the presence of Ku abolished the DNA-length dependency of the XLF–DNA association [53]. It is also possible to accommodate Ku70/80 heterodimer within the helical fibre of XRCC4/XLF [44].

In addition to the proteins bound within the central cavity of the XRCC4/XLF helical structure, there may be other NHEJ proteins assembled on the helical tail structures of XLF and XRCC4, which are pointing outward; this would be analogous to the assembly of proteins on the coiled-coil C-terminal regions in SAS-6. While LiggIV can bind to the XRCC4 coiled-coil tail, further proteins can also interact with the C-terminal extension of XRCC4, for example PNKP [54,55]. The folded-back loop sequence between XLF α4 and α5 is evolutionarily conserved. Site-directed mutagenesis studies of XLF at L174, R178 and L179, which are all located in this evolutionarily conserved hinge region, reduces the stimulation of the DNA end-ligation activity without affecting the association with XRCC4 or DNA [32]. This XLF conserved region of unknown function may bind to other, as-yet unidentified NHEJ proteins.

Recent studies in a mouse model have shown that XLF functionally overlaps with ataxia telangiectasia-mutated protein (ATM) and XLF/ATM double-deficiency severely impairs T- and B-cell development by impairing V(D)J recombination [56]. A possible explanation is that XLF influences processes such as DNA end tethering and protecting, which are also mediated by ATM and H2AX [56]. Therefore, the function of XRCC4/XLF may not only be restricted to the final DNA-end ligation step, it could assemble in early DNA synthesis right after Ku is recruited to the DNA damaged ends. The XRCC4/XLF helical filament may act as a dynamic and regulated ‘reaction shell’, which stabilizes chromatin near IR foci, and gathers Ku70/80 and DNA-PKcs together for efficient NHEJ function.

4. End processing

End processing has been structurally well studied with and without DNA. There are excellent reviews on structural studies of the X family DNA polymerase and PNKP [57,58]. Recent crystallographic studies of APTX have provided insights into how AMP is removed from 5′-adenylated DNA [59,60]. Here we concentrate on structural aspects of Artemis, mutation of which can cause radio-sensitive severe-combined immune deficiency (RS-SCID) [61]. Excellent reviews on biological and biochemical aspects of Artemis can be found elsewhere [62,63]. Artemis, a nuclease belonging to the metallo-β-lactamase superfamily [61,64], acquires endonuclease activity by forming a complex with DNA-PKcs, which is essential for the hairpin opening in V(D)J recombination [64]. Artemis itself has been associated with a 5′–to–3′ exonuclease activity [64] but a recent study suggests that this may arise from other exonucleases co-purified from expressed cells [65]. For instance, a homologue of Artemis, RNase J, carries both endo- and 5′–to–3′ exonuclease activities [66,67] and loses both activities upon mutation of key residues in its catalytic core [68]. However, mutations of conserved residues in Artemis impair only its endonuclease function [69]. As was suggested by the authors, Artemis might have sites that are responsible for the exonuclease activity.

Artemis has core metallo-β-lactamase (β-Lact) and β-CASP domains, which are conserved in nucleic acid-processing enzymes, as well as a C-terminal domain (Art-Cter), which is unique to Artemis [61,70]. Since the crystal structures of human paralogs of Artemis, CPSF-73 [71], Apollo and SNM1A (Unpublished structures; PDB codes: 3ZDK and 4BB7) are available in the Protein Data Bank and the catalytic core of Artemis shares 32% and 26% sequence identity with those of Apollo and SNM1A, the structures in complex with zinc atoms can be used to build a homology model of Artemis. The model, created using Modeller [72], shows a cleft between the β-Lact and β-CASP domains and interestingly that the β-Lact domain is comprised of two polypeptides separated by the β-CASP domain (Fig. 4A).

Conserved motifs 1–4 and A–C [70] are located in the β-Lact domain and are involved in the coordination of the catalytic divalent metal ions, which are zinc in most members of the superfamily. In the catalytic core, a zinc atom is likely to be coordinated by H33, H35 and H115 (Fig. 4B) because the equivalent zinc is present in the structure of the human paralogs. Although two zinc ions are present in the structures of CPSF-73 and Apollo, the metal ion interacting with acidic residues D37 & D136 and possibly E5 and E296 in Artemis could be magnesium and/or manganese for Artemis [64,69,73,74]; D165 is likely to form hydrogen bonds with the main chain amides of F137 & T167 and the side chain of H319, which is a key residue for the Artemis activity [69,75], suggesting that it is structurally important. The equivalent residue of H319 in Apollo interacts with a sulfate ion and tartaric acid implying that the histidine may bind DNA. Alternatively, the divalent ion might re-arrange to be coordinated by H319 and/or D165 during nuclease catalytic activity.

The sulfate superimposes well on a phosphorothioate of an RNA analog in the structure of an archaeal RNase belonging to the β-CASP family (PDB codes: 3IEM), indicating that the sulfate mimics a scissile phosphate. The structure of T. thermophilus RNase J in complex with RNA shows the presence of a pocket that 5′ monophosphate binds via direct contacts with H243, H372, S374, G375 and H376 [76]. In the archaeal structure, the 5′ phosphorothioate forms a salt bridge with R227 and a hydrogen bond with S378 (Fig. 4D), which are equivalent to H243 and S374 of the RNase J. SNM1A and Apollo have well-conserved lysines K883 & K186 and serines S992 & S274 at the equivalent positions of H243 and S374 of the RNase J. Indeed, K186 of Apollo makes a salt bridge with co-crystallized tartaric acid. Artemis is likely to have a similar serine
S317 but interestingly has a conserved tyrosine Y212 instead of lysine [70]. The difference is likely to be important for distinguishing exonuclease from endonuclease activity. In addition, Artemis is likely to have a longer loop than Apollo and SNM1A just after the first helix. Interestingly, the loop has a conserved-basic patch, which might bind the backbone of DNA.

Although the function of the β-CASP domain is not clear from the apo-structures, by analogy with the structure of archaean (PDB code: 3IEM) and bacterial [76] orthologs of Artemis, the domain may stabilize the conformation of nucleic acids in order to enable their cleavage. Interestingly, the β-CASP domain of Artemis and its paralogs have grooves with shallow pockets, which might bind DNA (Fig. 4C).

The C-terminal 300 residues (Art-Cter), which follow the core metallo-β-lactamase and β-CASP domains, are predicted to be mostly unstructured and seem to have a function in regulating Artemis endonuclease activities [73,77,78]. The details of how Art-Cter controls the endonuclease activity remain to be resolved. Importantly, the region has the DNA-PKcs and LigIV-binding motifs (residues 399–404 and 485–495, respectively) [79,80]. Recent crystallographic studies of the LigIV-binding region and LigIV complex show that Artemis and the first two helices of LigIV form a three-helical bundle mainly through hydrophobic interactions (Fig. 5B) [81,82]. Although the nature of the interaction remains to be investigated, it is clear that Artemis needs both the LigIV and DNA-PKcs interactions for an efficient coding-joint formation in V(D)J recombination [80].

In addition to these interactions, Art-Cter has PIKK phosphorylation sites concentrated after the LigIV-binding region [79,83–85]. The exact functions of the phosphorylations are not clear but they affect cell cycle [83,85] and localization [79]. If Art-Cter were highly phosphorylated after DNA damage, the net change of the region would be negative. Given that the similarity between a backbone phosphate and a phosphorylated sidechain, the phosphorylated C-terminal might interact with DNA-binding proteins including LigIV and regulate their functions. Indeed, there are examples of dynamic interactions between multi-phosphorylated peptides and globular domains [86]. Intriguingly, Artemis mutants lacking residues after T432 alter the N addition in V(D)J recombination [87], indicating that the region is important for TdT and/or pol μ functions. Since the truncated region has the LigIV-binding region, it is not clear whether LigIV or phosphorylation influence the polymerases, although both may do so because the polymerase interacts with Ku/LigIV/XRCC4 in a DNA-dependent manner [88–90].

5. End joining

DNA-end joining is carried out by the NHEJ ligase complex LigIV/XRCC4/XLF. This, as we have seen above, affects the activity and stability of LigIV [25,27,28,43,91–94]. XRCC4, XLF and the
BRCT domains of LigIV further interact with other NHEJ proteins, but the functions of the complexes formed are not very clear. Here we focus on recent structural studies of LigIV, which have provided insights into the catalytic and other roles of the catalytic region of the protein.

LigIV, one of three human DNA ligases, is present in all eukaryotes [95,96]. LigIV has the conserved catalytic region, which is present in the ligases, followed by tandem repeats of the BRCT domain at the C-terminus, which are unique among the ligases. The characteristic fold of the catalytic region can be found in archaeal [97–100] but not in prokaryotic DNA ligases. Since the BRCT domains of LigIV were reviewed previously [101], we focus here on the catalytic region of LigIV.

The catalytic region consists of the N-terminal DNA-binding domain (DBD), a nucleotidyltransferase or adenylation domain (NTD) and an OB-fold domain (OBD) (Fig. 5A). The latter two domains have seven conserved motifs (I, III, IIIa, IV, V, Va and VI) [102,103], most of which are essential in all nucleotidyltransferases for carrying out three steps of the nucleotidyltransfer reaction: the adenylation of the catalytic lysine (step 1), the transfer of AMP to 5’ phosphate (step 2) and the joining of DNA nick (step 3) [104]. The DNA ligases undergo large conformational changes during the reaction [105]. For human and archaeal DNA ligases, these are open, closed and DNA-bound conformations of the catalytic region in the PDB, which represent neutral, step 1 and steps 2 & 3 of the reaction, respectively.

LigIV can ligate incompatible DNA ends, across gaps at DNA ends and poly-T single strands [106,107]; this, with the exception of poly-T single strands, is stimulated by Ku and XLF [108,109]. An unusual characteristic of LigIV is that it is difficult re-adenylate after DNA ligation [110–113], a feature that is not present in the other ligases. These observations indicate that LigIV should have unique structural features that are absent from the other human DNA ligases, LigI and LigIII. The crystal structure of the catalytic region of LigIV shows four unique features (Inserts 1 & 2, Y298 and K345 in Fig. 5A) [51,82], which are probably important for the activity of LigIV.

Insert 1 is a loop connecting α5 and α6 of DBD while Insert 2 is present within OBD. OBD in DNA ligases has the conserved motif VI, which is essential for step 1 of DNA ligation [114]. Since motif VI needs to come close to the catalytic pocket to hydrolyze ATP, OBD undergoes a large conformational change to a closed conformation [105]. However, Inserts 1 and 2 stereochemically clash with OBD and DBD when LigIV has the closed conformation, a possible explanation as to why it is more difficult for LigIV to achieve the conformation and why the readenylation of LigIV is more difficult than in other human and archaeal DNA ligases. The difficulty of adenylation was observed in LigIV without XRCC4 [92] and LigIV/XRCC4 missing BRCT2 of LigIV [115]. Moreover, we have made similar observations in the dsDNA ligation assays of the catalytic region of LigIV with and without ATP [82], implying that the catalytic region of LigIV is responsible for the difficulty of readenylation.

XLF is known to stimulate readenylation of LigIV [25,93] and also interacts with LigIV via the first BRCT domain (BRCT1) [49]. It is unclear whether interactions of XRCC4 and XLF with LigIV take place in the context of the XRCC4/XLF filament, but they may induce conformational changes or stabilize the conformations of Inserts 1 and 2, in a way that favors the closed LigIV conformation, and stimulates adenylation.
A model of DNA-bound LigIV (Fig. 6A), based on the structures of LigI and LigIII in complex with nicked DNA [105,116], indicates that Insert 1, Y298 and K345 in NTD may be involved in the DNA-binding activity of LigIV [51,82]. Insert 1 may fit into a major groove located opposite to the DNA nick (Fig. 6B). Interestingly, the orientation of α5 with respect to α4 and α6 in DBD is different from that of the other human and archaeal DNA ligases. This might be correlated with the presence of Insert 1 and may be important for DNA ligation of the unusual substrates described above. Y298, a conserved residue in NTD of LigIV, could π stack with a base or sugar of DNA; this would be possible also in organisms where LigIV has a histidine or phenylalanine at the equivalent position.

The other residue in NTD, K345, thought to be involved in the DNA-binding activity of LigIV, is close to the 3’ OH end of the DNA nick. Most DNA ligases have phenylalanine at the equivalent position, and the structures of LigI and LigIII show that the phenylalanine π stacks with the 3’ end ribose. E. coli DNA ligase has arginine at the position, which is essential for the activity of the ligase [117,118]. The fact that LigIV has lysine at the position could reflect the need to detect the 3’ end flexibly. These unique features may allow LigIV to join different types of DNA ends so that DNA does not fall apart.

LigIII and LigIV but not LigI have end-joining activities towards DBSs [113]. However, although most of the DNA-binding affinity of LigI and LigIII come from DBD [105] (T.O. unpublished results), this is not true of LigII [119]. Instead, a jack-knife model of the DNA binding of LigIII has been proposed [116,119]. Then, the question arises as to how LigIV bridges two DNA ends. XRC4 itself forms protein filaments [37,38], which might help synopsis of DNA ends. Alternatively, LigIV might bind two fragments of DNA. Note that the linker between OB2 and BRCT1 of LigIV has been shown to have affinity for DNA [120]. Moreover, the non-catalytic function of LigIV is important for autophosphorylation of DNA-PKcs implying that LigIV is an important factor for synopsis [121]. Further biochemical including structural studies of how LigIV binds DNA are required to resolve this issue.

In addition to the features related to the catalytic activity, LigIV specifically interacts with Artemis (residues 485–495) [80]. Extensive hydrophobic interactions of the helical bundle mediated by V14, F42 and F49 of LigIV and W489, F492 and F493 of Artemis make the interaction moderately stable with 4.8 μM affinity [81,82] (Fig. 5B). It is unclear how the interaction affects the activities of LigI and/or Artemis. However, this interaction implies that LigIV can be recruited at DNA ends by Artemis forming a complex with DNA-PKcs and vice versa. Thus, multiple interactions among NHEJ proteins probably assemble them quickly and as stable complexes at DNA ends.

Lastly, we consider the specificity of LigIV in NHEJ. As mentioned above LigI, III and IV are likely to join two strands in a similar manner, suggesting that the catalytic regions of the ligases might replace each other with retention of function. Interestingly, mitochondrial LigIII can be replaced with LigI, LigIV and even DNA ligases from lower organisms [122,123]. It is difficult to know whether the catalytic regions of LigI and III replace that of LigIV because it is unclear whether the unique features of the catalytic region of LigIV are functionally important. However, LigI and III cannot compensate for full-length LigIV in LigIV-defective mouse [124], although LigIII can perform intermolecular ligation [113,119]. This is probably because interactions of LigIV with other macromolecules make the protein a specialized ligase for NHEJ. The interactions may be important for synopsis of correct DNA ends and/or allowing LigIV access to the ends. For instance, LigIV is specifically recruited to DNA ends by Ku [125,126] and displaces it from DNA ends [109]. Indeed, requirement of a non-catalytic function of LigIV for NHEJ has been reported [121]. In view of the fact that LigIV mutants with very weak catalytic activity cause LG4 syndrome (see below for the details), NHEJ likely needs both catalytic and non-catalytic functions of LigIV. However, it does not eliminate the possibility that LigI and III ligate a tiny fraction of DSBs in the final step of NHEJ. Thus, it would be interesting to see whether ligases work in NHEJ in the presence of enzymatically inactive LigIV, e.g., having a mutation on K273, in order to see whether the mutation causes LG4 syndrome or embryonic lethal. When the core components of NHEJ are missing, AEJ takes over. The zinc-finger domain of LigIII promotes DNA ligation near single-strand gaps and flaps [127], which are likely to be intermediate states of damaged DNA in AEJ, as well as intermolecular ligation [127,119]. The domain interacts with PARP-1 [128], which has been reported to play a role in AEJ [129–132]. Importantly, the zinc-finger domain is dispensable for microhomology-mediated AEJ [133]. Moreover, the same authors showed that the BRCT domain of LigIII is inessential for AEJ indicating that the ligase does not need XRCC1 for the joining. LigI also works in an alternative pathway of DSB-end joining [133,134] implying the existence of two different pathways for AEJ and a hierarchy among LigIV, III and I for the end joining [133]. Although the hierarchical mechanism remains to be elucidated, competition and crosstalk, if present among proteins involving end joining such as the ligases, Ku, PARP-1 and PAR, may decide which ligase to recruit to DSB ends. In fact, Ku directly competes with PARP-1 for DSB repair [130].
6. NHEJ deficiency

Mutations in ARTEMIS, LIG4 and XLF genes are known to cause radiosensitive immune deficiency. The ARTEMIS gene deficiency, most frequently reported among NHEJ genes, leads to radiosensitive severe-combined immunodeficiency (RS-SCID) or Omenn syndrome [61,135]. Mutations vary from point mutations to null expression [136]. Most of the point mutants, including S32C [62], S32F [137], D173G [138], G185V, G135E [139] and D165V [136], are concentrated near the catalytic center of Artemis (Fig. 4A), indicating a probable loss or reduction of endonuclease function; this is confirmed by mutagenesis studies of some of the residues [69,75]. Mutations of two buried residues outside the catalytic center, I16T and A28P (Fig. 4A) found in some radiosensitive immune deficient patients [136,140], are predicted by SDM analysis [141] to result in structural instability of the β-Lact domain. It is difficult to predict the impacts of mutations G126D [142] and G153R [137], which are located in loops (Fig. 4A), without in vitro data and knowing the correct conformation of loop structures from the crystal structure of Artemis. P171 is in the loop connecting the β-Lact and β-CASP domains (Fig. 4A) [143]. However, a conserved proline, present at a similar position in the structures of SNM1A and Apollo, is stacked on a tyrosine in the second sub-domain of β-Lact. Since Artemis also has a tyrosine at the corresponding location, the mutation P171R may change local structure as proposed by Jeggo and colleagues [143]. Three mutations causing radiosensitive immune deficiency, G211V, H228N [136] and H254L [144], are present in the β-CASP domain (Fig. 4A). At a similar position to G211, SNM1A and Apollo have G882 and G185, which are solvent inaccessible and have positive β torsion angles; therefore, G211V is likely to disrupt the local conformation around the residue. H254L, as indicated by a SDM analysis, destabilizes the β-CASP domain because it makes a hydrogen bond with the carbonyl oxygen of T251 (Fig. 7). Since H228 and H254 are conserved residues in the groove mentioned above in our discussion of end processing, they might have important functions apart from structural roles.

LigIV/XRCC4 is important for normal growth because the knockout of either LIG4 or XRCC4 gene is embryonic lethal [124,145,146], and moreover, hypomorphic mutations of LigIV or XLF in human cause rare diseases characterized conventionally by radiosensitivity, immunodeficiency, microcephaly, etc.: growth retardation and microcephaly caused by mutations in LIG4 are classified as LIG4 syndrome [147,148]. Recent crystallographic studies of human

---

**Fig. 8.** XLF mutants in Cernunnos-XLF deficiency patients. (A) R57, polar interaction is indicated by grey dashed line; (B) C123; (C) A25-R57 deletion. (D) R178X. Deletion protein sequences are shown in grey color.
LigIV have shed light on some point mutations, such as A3V, T9I, M249V, R278H, Q280R, H282L and G469E, which are found in LigIV syndrome patients [149–155]. A3 and T9 are located in the flexible N-terminal region and the beginning of the first α-helix of DBD, respectively. The residues before T6 were not observed in the crystal structures of DBD [81,82], indicating that A3V is unlikely to affect structural stability or activity of LigIV. However, the increase of hydrophobicity [150] in an exposed, unstructured region caused by substitution of alanine by valine could introduce non-specific protein-protein interactions, which may interfere with the activity of LigIV. T9 stabilizes the conformation of a short α-helix connected to the following helix by a kink produced by a VPF motif. Mutation T9I may alter the local conformation, affecting the interaction with Artemis and/or DNA. The mutation increases the risk of developing severe radiation pneumonitis in some patients after radiation therapy [156]. Interestingly, A3V and T9I have protective effects on the development of multiple myeloma but cause severe clinical phenotypes when combined with R278H [157].

M249, R278, Q280, H282 and Y288, all located in NTD, are likely to be important for structural stability of the ATP-binding pocket. R278 is the only residue of this group that might interact directly with ATP [111]. R278, Q280 and H282 stabilize the conformation of the region that influences interactions between the two subdomains of NTD. Since the ATP-binding pocket lies between the subdomains, it is likely that M249V, R278H, Q280R and H282L lead to instability or conformational change in the ATP-binding pocket, resulting in a large reduction of the adenyllyation efficiency as reported for R278H [149]. G469, a residue in motif Va, which is important for the adenylation of LigIV [103], is completely buried and surrounded by large hydrophobic residues. Therefore, it is likely that G469E leads to disruption of the conformation of DBD.

In summary, apart from A3V and T9I, point mutations found in LigIV syndrome mutations cause conformational changes and/or structural instabilities in LigIV.

Five patients, who have Cernunos-XLF deficiency caused by mutations in XLF gene, have been identified so far [33]. These mutations, involving deletion between A25–R57, R57G, C123R, and R178X and resulting in truncated putative proteins, lead to severely reduced protein levels. Mutation of R57G (α2) results in loss of R57 side chain interactions with E47 (B4) and N120 (B7), which are crucial for maintaining the β-sandwich structure (Fig. 8A). C123R (β7) mutation disrupts its hydrophobic core environment created by W45 (B4), E47 (B4), Y34 (B3), L36 (B3), V38 (B3), L104 (B6), L106 (B6) and F121 (B7) (Fig. 8B). Deletion of residues between A25–R57 leads to the absence of β-2 and half of α2 (Fig. 8C). Therefore A25–R57 deletion, R57G and C123R mutations can destabilize the XLF head domain structure and affect its function. Biochemical experiments on XLF mutant R57G also show that change of head domain conformation can result in loss of XLF ability to translocate into the nucleus properly [27]. R178X mutant is missing the fold back structure (α5, α6) and flexible C-terminal of XLF (Fig. 5D). Therefore it lacks the helix to maintain its homodimeric structure, and region for DNA interaction and Ku binding.

7. Conclusion

Recent studies of NHEJ proteins have revealed diverse functions, which emphasize the need to reconsider the conventional NHEJ model. In this review we have focused on structural aspects of interactions of LigIV with XRCC4, XLF, Artemis and DNA, seeking to use these to inform our understanding of the spatial and temporal organization of NHEJ. We show that structural studies of LigIV/XRCC4/XLF and LigIV/Artemis complexes can shed light on their interactions at an amino-acid level, which can then be investigated in vivo using site-directed mutagenesis.

The DNA-double-strand-break repair process is an example of the complexity of multicomponent systems in the cell that are required to assemble and disassemble in response to signals from outside. The complexity ensures the proper location of components in space and time, and thus accurate and timely responses to signals outwith and within NHEJ both in immune cells and when DNA damage occurs.

Knowledge of the spatial organization and interactions between the many components of NHEJ will likely be useful for developing specific inhibitors to block the NHEJ pathway. Indeed, inhibitors of human DNA ligases including LigIV have been studied [158] and recently demonstrated to be potential drugs for cancer therapy [159]. With developing expertise in targeting protein–protein interactions [160], these complex molecular assemblies of known structure will likely become attractive targets for the development of therapeutic agents that can be used in combination with classical radio or chemotherpay.

Conflict of interest

The authors declare that there are no conflicts of interest.

Acknowledgement

T.O., Q.W. and T.L.B. are supported by Wellcome Trust. We thank Drs. Dimitri Y. Chirgadze and Banciynane L. Sibanda for helpful discussion.

References

[1] M.R. Lieber, The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway, Annu. Rev Biochem. 79 (2010) 181–211.
[2] S.J. Boulton, S.P. Jackson, Saccharomyces cerevisiae Ku70 potentiates illegitimate DNA double-strand break repair and serves as a barrier to error-prone DNA repair pathways, EMBO J. 15 (1996) 5093–5103.
[3] D.B.R. Molly, A. Bagie, Chiyu Wang, Chengming Zhu, VDJ Recombination in Ku86-deficient mice: distinct effects on coding, signal, and hybrid joint formation, Immunity 7 (1997) 37–47.
[4] E. Kabotyanski, L. Gomelsky, J. Han, T. Stamatou, D. Roth, Double-strand break repair in Ku86- and XRCC4-deficient cells, Nucl. Acids Res. 26 (1998) 5333–5342.
[5] H. Wang, A.R. Perrauff, T. Takeda, W. Qin, H. Wang, G. Ilakis, Biochemical evidence for Ku-independent backup pathways of NHEJ, Nucl. Acids Res. 31 (2003) 5377–5388.
[6] C. Boboila, C. Yan, D.R. Wesemann, M. Jankovic, J.H. Wang, J. Manis, et al., Alternative end-joining catalyzes class switch recombination in the absence of both Ku70 and DNA ligase 4, J. Exp. Med. 207 (2010) 417–427.
[7] N. Dimitrovova, Y.-C.M. Chen, D.L. Spector, T. de Lange, 53BP1 promotes non-homologous end joining of telomeres by increasing chromatin mobility, Nature 456 (2008) 524–528.
[8] S. Dhillonpanthino, E. Gapud, N. Wong, C.-Y. Huang, G. Mahowald, H.T. Chen, et al., 53BP1 facilitates long-range DNA end-joining during V(D)J recombination, Nature 456 (2008) 529–533.
[9] M. Zimmermann, F. Lottersberger, S. Buonomo, A. Sfeir, T. de Lange, 53BP1 regulates DSB repair by RIF1 to control 5′ end resection, Science (80-. ) 339 (2013) 700–704.
[10] M. Di Virgilio, E. Callen, A. Yamane, W. Zhang, M. Jankovic, A. Gitlin, et al., RIF1 prevents resection of DNA breaks and promotes immunoglobulin class switching, Science (80-. ) 339 (2013) 711–715.
[11] R. Chapman, P. Barral, J.-B. Vannier, V. Borel, M. Steger, A. Tomas-Loba, et al., RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resection, Mol. Cell. (2013).
[12] C. Escribano-Diaz, A. Orthwein, A. Fradet-Turcotte, M. Xing, J. Young, T. Tkalec, et al., A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CIP1 controls DNA repair pathway choice, Mol. Cell. (2013).
[13] C.Y. Chiu, R.B. Cary, D.J. Chen, S.R. Peterson, P.L. Stewart, Cryo-EM imaging of the catalytic subunit of the DNA-dependent protein kinase, J. Mol. Biol. 284 (1998) 1075–1081.
[14] K. Leuther, O. Hammersen, R. Kornberg, G. Chiu, Structure of DNA-dependent protein kinase: implications for its regulation by DNA, EMBO J. 18 (1999) 1114–1123.
[15] J. Bosková, A. Rivero-Calzada, J.D. Maman, P. Chacón, K.R. Willison, L.H. Pearl, et al., Visualization of DNA-induced conformational changes in the DNA repair kinase DNA-PKcs, EMBO J. 22 (2003) 5875–5882.
the structure, with M.

S.

D.J.

Barbeau, N.

Curtin,

(2002).

symmetry of bacteria: the EMBO structures related to DNA end-joining, Cell 124 (2006)

91–96.

Y. Flückiger, et al., Interplay between cernunnos/XLF and nonhomologous end-joining proteins at DNA ends in the cell, J. Biol. Chem. 282 (2007) 31937–31943.

K. Aposontis, R.-Z.Z. Zhou, S. Mohapatra, K. Valerie, S.P. Lees-Miller, K.-J. Lee, et al., Requirement for XLF in aligment-based gap filling by DNA polymerases lambda and mu for nonhomologous end joining in human cells, EMBO J. 27 (2008) 290–300.

L. Münzel, S. Crichlow, J. Begen, X. Pei, S. Jackson, T. Blundell, et al., Crystal structure of an Xrc4-DNA ligase IV complex, Nat. Struct. Biol. 8 (2001) 1015–1019.

Y. Li, D.Y. Chigardie, V.M. Bolanos-García, B.L. Sibanda, O.R. Davies, P. Ahnsson, et al., Structural and functional analysis of human XLF, Trends Biochem. Sci. 36 (2011) 2462–2467.

F. Wang, M. Stadler, B. Varga, P. Frit, M. Bouvier, D.J. Decimo, et al., Structural and functional interaction between the human DNA repair proteins DNA ligase IV and XRC4, Mol. Cell. Biol. 29 (2009) 3163–3172.

A.S. Doré, N. Furnham, O.R. Davies, B.L. Sibanda, D.Y. Chigardie, S.P. Jackson, et al., Structure of an Xrc4-DNA ligase IV complex reveals a novel BRCT interaction mode, DNA Repair (2005) 362–368.

T. Ochi, Q. Wu, D. Chigardie, G. Grossmann, V. Bolanos-García, T. Blundell, Structural insights into the role of domain flexibility in human DNA ligase IV, Structure 20 (2012) 1212–1222.

K. Aposontis, R.-Z.Z. Zhou, S. Mohapatra, K. Valerie, S.P. Lees-Miller, K.-J. Lee, et al., Requirement for XLF in aligment-based gap filling by DNA polymerases lambda and mu for nonhomologous end joining in human cells, EMBO J. 27 (2008) 290–300.

L. Münzel, S. Crichlow, J. Begen, X. Pei, S. Jackson, T. Blundell, et al., Crystal structure of an Xrc4-DNA ligase IV complex, Nat. Struct. Biol. 8 (2001) 1015–1019.

Y. Li, D.Y. Chigardie, V.M. Bolanos-García, B.L. Sibanda, O.R. Davies, P. Ahnsson, et al., Structural and functional analysis of human XLF, Trends Biochem. Sci. 36 (2011) 2462–2467.

F. Wang, M. Stadler, B. Varga, P. Frit, M. Bouvier, D.J. Decimo, et al., Structural and functional interaction between the human DNA repair proteins DNA ligase IV and XRC4, Mol. Cell. Biol. 29 (2009) 3163–3172.

A.S. Doré, N. Furnham, O.R. Davies, B.L. Sibanda, D.Y. Chigardie, S.P. Jackson, et al., Structure of an Xrc4-DNA ligase IV complex reveals a novel BRCT interaction mode, DNA Repair (2005) 362–368.

T. Ochi, Q. Wu, D. Chigardie, G. Grossmann, V. Bolanos-García, T. Blundell, Structural insights into the role of domain flexibility in human DNA ligase IV, Structure 20 (2012) 1212–1222.

K. Aposontis, R.-Z.Z. Zhou, S. Mohapatra, K. Valerie, S.P. Lees-Miller, K.-J. Lee, et al., Requirement for XLF in aligment-based gap filling by DNA polymerases lambda and mu for nonhomologous end joining in human cells, EMBO J. 27 (2008) 290–300.

L. Münzel, S. Crichlow, J. Begen, X. Pei, S. Jackson, T. Blundell, et al., Crystal structure of an Xrc4-DNA ligase IV complex, Nat. Struct. Biol. 8 (2001) 1015–1019.

Y. Li, D.Y. Chigardie, V.M. Bolanos-García, B.L. Sibanda, O.R. Davies, P. Ahnsson, et al., Structural and functional analysis of human XLF, Trends Biochem. Sci. 36 (2011) 2462–2467.

F. Wang, M. Stadler, B. Varga, P. Frit, M. Bouvier, D.J. Decimo, et al., Structural and functional interaction between the human DNA repair proteins DNA ligase IV and XRC4, Mol. Cell. Biol. 29 (2009) 3163–3172.

A.S. Doré, N. Furnham, O.R. Davies, B.L. Sibanda, D.Y. Chigardie, S.P. Jackson, et al., Structure of an Xrc4-DNA ligase IV complex reveals a novel BRCT interaction mode, DNA Repair (2005) 362–368.

T. Ochi, Q. Wu, D. Chigardie, G. Grossmann, V. Bolanos-García, T. Blundell, Structural insights into the role of domain flexibility in human DNA ligase IV, Structure 20 (2012) 1212–1222.
Clin. Acad. (2012) 53–58.

A. Dorkès, L. li de la Sierra-Galaly, J. Piton, L. Zig, L. Gilet, H. Putzer, et al., Molecular basis for the recognition and cleavage of RNA by the bifunctional 5′-3′ exo/endo ribonuclease L. Structure 19 (2011) 1252–1261.

Y. Ma, U. Pannicke, K. Schwarz, M.R. Lieber, The DNA-dependent protein kinase catalytic subunit phosphotyrosine sites in human Artemis, J. Biol. Chem. 280 (2005) 33839–33846.

D. Furda, U. Pannicke, H. Lu, Y. Ma, L.-C. Wang, P. Kulesza, et al., DNA-PKcs dependence of Artemis endonuclease activity, differences between hairpins and 5′ or 3′ overhangs, J. Biol. Chem. 281 (2006) 33900–33905.

S. Soubeyrand, L. Pope, R. De Chasseval, D. Gosselin, F. Dong, J.-F. De Villartay, et al., Artemis and DNA-dependent protein kinase alpha preferentially with discrete regions of chromatin, J. Mol. Biol. 358 (2006) 1200–1211.

S. Malu, P. De Ioannes, M. Kozlov, M. Greene, D. Francis, M. Hanna, et al., Artemis C-terminal region facilitates V(D)J recombination through its interactions with DNA Ligase IV and DNA-PKcs, J. Exp. Med. 209 (2012) 955–963.

P. De Ioannes, S. Malu, P. Cortes, A. Aggarwal, Structural basis of DNA ligase IV–artemis interaction in nonhomologous end-joining, Cell Rep. 2 (2012) 1505–1512.

T. Ochi, X. Gu, T. Blundell, Structure of the catalytic region of DNA ligase IV in complex with an artifical fragment sheds light on double-strand break repair, Structure 21 (2013) 672–679.

X. Zhang, J. Succi, Z. Feng, S. Prithivirajasingh, M.D. Story, R.J. Leger, Artemis is a phosphorylation target of ATM and ATR and is involved in the G2/M DNA damage checkpoint, J. Cell Biol. 24 (2004) 3071–3081.

L. Chen, T. Morio, Y. Minegishi, S.-I. Nakada, M. Nagasawa, K. Komatsu, et al., Ataxia-telangiectasia-mutated dependent phosphorylation of Artemis in response to DNA damage, Cancer Sci. 96 (2005) 134–141.

J. Wang, J. Pluth, P. Cooper, M. Cowan, D. Chen, S. Yannone, Artemis deficiency confers a DNA double-strand break repair defect and Artemis phosphorylation status is altered by DNA damage and cell cycle progression, Repair 5 (2006) 556–567.

T. Mittag, L. Kay, J. Forman-Kay, Protein dynamics and conformational disorder in molecular recognition, J. Mol. Recognit. 23 (2010) 105–116.

D. Moshos, C. Pannetier, R. de Chasseval, F. de Leitl Fl, M. Cavazzana-Calvo, S. Delpech, et al., ParatB and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis, J. Clin. Invest. 113 (2003) 381–387.

K. Mahajan, L. Gangi-Peterson, D. Sorscher, J. Wang, K. Gathy, N. Mahajan, et al., Association of terminal deoxynucleotidyl transferase with Ku, Proc. Natl. Acad. Sci. 96 (1999) 13926–13931.

K.N. Mahajan, B.S. Nick, D.A. Mitchell, Ramsden, Association of DNA polymerase micro (pol micro) with Ku and ligase IV, role for pol micro in end-joining double-strand break repair, Mol. Cell. Biol. 22 (2002) 5194–5202.

Y. Ma, H. Lu, B. Tippin, M.F. Goodman, N. Shimazaki, O. Kowai, et al., A biochemically defined system for mammalian nonhomologous DNA end joining, Mol. Cell. Biol. 16 (2006) 7131–7137.

U. Grawunder, D. Zimmer, M.R. Lieber, DNA ligase IV binding to XRCC4 via a motif located between rather than within its BRCT domains, Curr. Biol. 8 (1998) 743–748.

Y. Wang, B.J. Lamarche, M.-D.D. Tsai, Human DNA ligase IV and the ligase IV/XRC4 complex: analysis of nick ligation fidelity, Biochemistry 46 (2007) 4962–4976.

X. Chen, A.E. Tomkinson, Yeast Nej1 is a key participant in the initial end binding and final ligation steps of nonhomologous end joining, J. Biol. Chem. 286 (2011) 4931–4940.

M. Bryans, M.C. Valenzano, T.D. Stamatos, Absence of DNA ligase IV protein in XR-1 cells; evidence for stabilization by XRCC4, Mutat. Res. Repair 433 (1999) 53–58.

Y. Wei, P. Robins, K. Carter, K. Caldecott, D. Pappin, G. Yu, et al., Molecular cloning and expression of human CDNAS encoding a novel DNA ligase IV and DNA ligase III, an enzyme active in DNA repair and recombination, Mol. Cell. Biol. 15 (1995) 2306–2316.

A.E. Tomkinson, S. Vijayakumar, J.M. Pascal, T. Ellenberger, DNA ligase IV: structure, reaction mechanism, and function, Chem. Rev. 106 (2006) 687–699.

J.M. Pascal, O.V. Tsodikov, G.L. Hura, W. Song, E.A. Cotner, S. Classen, et al., A flexible interface between DNA ligase and PCNA supports covalent ligation and MD5–275–297, J. Exp. Med. 200 (2004) 1347–1352.

H. Nishida, S. Kiyonari, Y. Ishino, K. Morikawa, The closed structure of an archael DNA ligase from pyrococcus furiosus, J. Mol. Biol. 360 (2006) 950–968.

D. Kim, O. Kim, H. Kim, H. Kim, S. Lee, S. Suh, ATP-dependent DNA ligase from {\textit{Archaeoglobus fulgidus}} displays a tightly closed conformation, Acta Crystallogr. Sect. F 65 (2009) 544–550.

T. Vries, E.Y. Panyutin, K.M. Abo, M.V. Mardanov, K. Pomykov, V.Y. Volkov, et al., ATP-dependent DNA ligase from Thermococcus sp. 1519 displays a new arrangement of the OB-fold domain, Acta Crystallogr. Sect. F 68 (2012) 0.
Lieber,

95

Ligase for cellular patient, upon DNA Nucleic J. M. Noordzij, al., al., Ege, (2005) Wiegant, immunodeficiency, to Chistiakov, 8 Mansour, switch ligases Mutat. with ARTEMIS der 15 Y. Y. Artemis Sun, V. V. V. V. et N. 52 DNA gene-corrected with ARTEMIS and radiosensitivity, and severe radiation pneumonia in nonsmall cell lung cancer patients treated with definitive radiotherapy, Cancer 118 (2012) 528–535.

P.L. Roddam, S. Rollinson, M. O’Driscoll, P.A. Jegg, A. Jack, C.J. Morgan, Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination, J. Med. Genet. 39 (2002) 900–905.

X. Chen, S. Zhong, X. Zhu, D. Dziegielewskia, T. Ellenberger, G.M. Wilson, et al., Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair, Cancer Res. 68 (2008) 3169–3177.

M. Srivastava, M. Nambar, S. Sharma, S. Kirk, G. Goldsmith, M. Hegde, et al., An X-ray crystal structure of nonhomologous end-joining protein Parp1, Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 11920–11924.

T.M. Gottlieb, S.P. Jackson, The DNA-dependent protein kinase: requirement for DNA double-strand breaks and endpoints, Curr. Opin. Cell Biol. 13 (2001) 522–527.

U. Grawunder, M. Wilm, X. Wu, P. Kulesza, T.E. Wilson, M. Mann, et al., Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells, Nature 388 (1997) 492–495.

S.E. Critchlow, R.P. Bowater, S.P. Jackson, Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV, Curr. Biol. 7 (1997) 588–598.

K.N. Mahajan, S.A. Nick McElhinny, B.S. Mitchell, D.A. Ramsden, Association of DNA polymerase mu (pol mu) with Ku and ligase IV: role for pol mu in end-to-end double-strand break repair, Mol. Cell. Biol. 22 (2002) 5194–5202.

C. Koch, R. Agyei, S. Galicia, P. Metalnikov, P.O’Donnell, A. Starostine, et al., Xrc4 physically links DNA end processing by polynucleotide kinase to DNA ligation by DNA ligase IV, EMBO J. 23 (2004) 3874–3885.

P.M. Clements, C. Breslin, D.E. Deeks, P.J. Byrd, L. Ju, P. Bieganowski, et al., The ataxia-oculomotor apraxia 1 gene product has a role distinct from ATM and interacts with the DNA strand break repair proteins XRCC1 and XRCC4, DNA Repair (Amst) 3 (2004) 1493–1502.

S. Kann, H. Kurosaka, S. Saza, Z. Hong, L. Lan, S. Nakajima, et al., A novel human AP endonuclease with conserved zinc-finger-like motifs involved in DNA strand break responses, EMBO J. 26 (2007) 2094–2103.

S. Ruiten, F. Cortes-Ledesma, L. Guo, K.W. Caldwell, APLF (Czorf13) is a novel component of poly(ADP-ribose) signalling in mammalian cells, Mol. Cell. Biol. (2008).

G. Grundy, S. Ruiten, Z. Zeng, R. Arribas-Bosacoma, N. Iles, K. Manley, et al., APLF promotes the assembly and activity of non-homologous end joining protein complexes, EMBO J. (2012).

S. Gore, A. Karmali, T. Blundell, Raptertas: a versatile engine for discrete restraint-based conformational sampling of macromolecules, BMC Struct. Biol. 7 (2007).